Victory Capital Management
CMPX icon

Victory Capital Management’s Compass Therapeutics CMPX Stock Holding History

Victory Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4K Buy
14,806
+1,077
+8% +$3.18K ﹤0.01% 2422
2026
Q1 		$72.6K Sell
13,729
-582
-4% -$3.36K ﹤0.01% 2293
2025
Q4 		$76.8K Buy
14,311
+1,659
+13% +$7.66K ﹤0.01% 2297
2025
Q3 		$44.3K Buy
12,652
+2,164
+21% +$6.83K ﹤0.01% 2351
2025
Q2 		$27.3K Buy
+10,488
New +$21.6K ﹤0.01% 2424
2025
Q1 		– Sell
-10,536
Closed -$15.3K – 2487
2024
Q4 		$15.3K Sell
10,536
-356
-3% -$591 ﹤0.01% 2458
2024
Q3 		$20K Sell
10,892
-573
-5% -$714 ﹤0.01% 2443
2024
Q2 		$11.5K Buy
11,465
+1,444
+14% +$2.11K ﹤0.01% 2461
2024
Q1 		$19.8K Sell
10,021
-1,010
-9% -$1.75K ﹤0.01% 2445
2023
Q4 		$17.2K Buy
+11,031
New +$19.1K ﹤0.01% 2514

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Victory Capital Management's CMPX Position: Q2 2026 in Review

Victory Capital Management increased its Compass Therapeutics (CMPX) stake by 7.8% in Q2 2026, buying an estimated $3.18K and bringing the position to 14,806 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Victory Capital Management first reported a position in CMPX in Q4 2023 and has held it in 10 quarters since. The position peaked at $76.8K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Victory Capital Management held 14,806 shares of Compass Therapeutics worth $32.4K as of Q2 2026.
  • Victory Capital Management bought 1,077 Compass Therapeutics shares in Q2 2026, an estimated $3.18K.
  • Compass Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2422 holding.
  • Victory Capital Management first reported a position in Compass Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Victory Capital Management's Compass Therapeutics position peaked at $76.8K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.